Kornimate/medical-research-clean huggingface dataset:
intensity-modulated stereotactic radiation therapy in treating patients with grade ii-iv glioma

Conditions: Glioblastoma; WHO Grade II Glioma; WHO Grade III Glioma

Summary: this phase ii trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade ii-iv glioma. stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

primary objectives: i. to determine the effect of intensity-modulated (im)-stereotactic radiotherapy (srt) on the incidence of wound infection (requiring oral/intravenous \[iv\] antibiotics or surgery), or wound dehiscence. secondary objectives: i. to determine the effect of im-srt on the incidence of titanium implants as palpable cranial defects due to scalp thinning. ii. to determine the effect of im-srt on the incidence of hair loss and recovery rate. iii. to determine the effect on quality of life (qol) using european quality of life five dimension five level scale questionnaire (eq-5d-5l). tertiary objectives: i. to determine if treatment of intensity-modulated stereotactic radiotherapy (im-srt) in patients with newly diagnosed grade ii-iv gliomas can decrease the loss of scalp thickness in the coronal plane in t-1w magnetic resonance (mr) images.

Eligibility criteria:
inclusion criteria: * patients must have histologically confirmed low or high grade glioma (grade ii-iv) * karnofsky performance status (kps) \>= 60 * patients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment * estimated survival \>= 3 months * labs considered acceptable per standard of care * patient must sign a study specific informed consent form * radiation treatment must begin \>= 3 weeks and =\< 8 weeks after surgery exclusion criteria: * prior history of scalp radiation or intolerance to standard course of radiation treatment * co-morbidities that would influence wound healing including diabetes (insulin dependent) or smoking (current ongoing use) * pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * karnofsky performance status (kps) \< 60 * patient can't have magnetic resonance imaging (mri) scan * active collagen vascular disease
cavent-ventilation during advanced cardiopulmonary resuscitation in out-of-hospital cardiac arrest- a descriptive study

Conditions: Out-of-Hospital Cardiac Arrest; Pulmonary Ventilation

Summary: the aim with this descriptive multicenter study is to examine the quality of the ventilation given by emergency medical service (ems) personnel during cardiopulmonary resuscitation (cpr). primary endpoint is the ventilation quality measured as ventilation frequency, tidal volume and minute ventilation. this will primarily be studied during cpr with a 30 compression/2 ventilation ratio performed by the ems personnel where the airway is managed with a supraglottic device but also in cpr with continuous ventilation (8-10 breaths/minute) after the airway management have been replaced with an endotracheal within the emergency room. the inclusion of patients will be performed at two sites (uppsala; sweden and utrecht; holland), all out-of-hospital cardia arrest (ohca) patients will receive care according to current cpr guidelines using mechanical chest compressions.

the inclusion is estimated to run over a two-year period to reach the goal of at least 200 patients. the study has been preceded by a trial period in an effort to solve any logistic and technical problems. the study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during cpr by ems treating patients with ohca. any results from standard laboratory tests related to ventilation quality will be retracted from the patient medical journal systems. in addition to ventilatory variables measured as endpoints, secondary endpoints will also be outcome measures as any rosc, survival and neurological outcome (mrs, gos-e) measured at 30 days and at 6 months.

Eligibility criteria:
inclusion criteria: out-of-hospital cardiac arrest (ohca) treated with cpr performed by the ems personnel exclusion criteria: * patient age \< 18 years * known pregnancy * trauma related cardiac arrest (inc. hanging)

Keywords: out-of-hospital cardiac arrest cardiopulmonary resuscitation respiration, artificial
applying social comparison theory to behavioral weight loss: does modifying group membership improve outcome?

Conditions: Obesity

Summary: the purpose of this study is to determine whether a modified behavioral treatment for weight loss that includes one-on-one treatment for individuals struggling to lose weight is associated with more weight loss than a standard behavioral treatment.


Eligibility criteria:
inclusion criteria: * bmi between 27 and 45 kg/m2 exclusion criteria: * participating in a weight loss program or taking a weight loss medication * currently pregnant, lactating, or less than 6-months post-partum or plan to become pregnant during the time of the intervention. * report a heart condition, chest pain during periods of activity or rest, or loss of consciousness * report conditions that would render the participant unlikely to follow the study protocol (e.g., terminal illness, relocation, substance abuse, sever psychiatric condition, dementia).
impact of a lcd on metabolic inflexibility and cardiovascular risk in liver transplant patients

Conditions: Weight Gain

Summary: this study is looking to see how a 6-month low carbohydrate diet can affect the body's ability to use energy in addition to the affects it has on the heart and blood vessel health.

weight gain often occurs following a liver transplant. this weight gain is problematic as it leads to many other health problems. the reasons of this weight gain are still poorly understood. to better understand weight gain, this study is looking to see how a 6-month low carbohydrate diet can affect the body's ability to use energy in addition to the affects it has on heart and blood vessel health. this study will help researchers to better understand weight gain after a transplant. this knowledge will help doctors prevent weight gain after a liver transplant and therefore improve the health of liver transplant patients.

Eligibility criteria:
inclusion criteria: * age \> 18 years * at least 12 months after lt * obese (bmi \> 30kg/m2) exclusion criteria: * acute cellular or chronic rejection within 3 months * post-lt liver or non-liver related malignancy * active viral hepatitis (b or c), autoimmune hepatitis * untreated biliary strictures or vascular complications (i.e. hepatic artery thrombosis) * poorly controlled diabetes mellitus * relapse of alcohol abuse after lt * stage 5 chronic kidney disease * current pregnancy

Keywords: liver transplant, low carbohydrate diet
anti-gingivitis mouthrinse

Conditions: Gingivitis

Summary: the purpose of this study is to prove whether a fluoride/zinc lactate containing mouthrinse is able to reduce dental plaque and gingival inflammation in patients who have gingivitis when applied twice daily during brushing at home over a period of 12 weeks.


Eligibility criteria:
inclusion criteria: * availability for the six-month duration of the clinical research study. * good general health. * minimum of 20 uncrowned permanent natural teeth (excluding third molars). * initial gingivitis index of at least 1.5 as determined by the use of the gingival index (löe 1967). * initial plaque index of at least 1.5 as determined by the use of the plaque index (turesky et al. 1970). * signed informed consent form. exclusion criteria: * presence of orthodontic bands. * malign tumor(s) of the soft or hard tissues of the oral cavity. * antibiotic use any time during the one-month period prior to entry into the study. * participation in any other clinical study or test panel within the one month prior to entry into the study. * dental prophylaxis during the past two weeks prior to baseline examinations. * history of allergies to oral care/personal care consumer products or their ingredients. * on any prescription medicines that might interfere with the study outcome. * an existing medical condition that prohibits eating or drinking for periods up to 4 hours. * history of alcohol or drug abuse. * self-reported pregnant or lactating subjects. * participants who have systemic diseases that require regular systemic medication intake that may affect the gingival condition (e.g. antibiotics, phenytoin, nifedipine, cyclosporine, steroids, antiphlogistics). * participants who require antibiotic treatments for dental appointments. * participants with current moderate or severe chronic or aggressive periodontitis (periodontitis screening index \[psi\] \>2 in more than 2 sextants or psi \>3). * subjects with caries requiring treatment (e.g., caries with cavity) or other oral diseases (including gingival hyperplasia, diseases of the oral mucosa); * smokers or/and users of tobacco products. * persons, who are unable to give their consent (e.g., persons who have limited legal capacity)
novel probiotic treatment for prevention of recurrent utis in children

Conditions: Recurrent UTIs; Catheter-Related Infections

Summary: background: urinary tract infections (utis) are a common and costly cause of doctor visits for children. frequent utis trigger kidney damage that leads to serious diseases like high blood pressure, pregnancy complications, and kidney failure. treating utis with preventative antibiotics has not shown improvement of the risk of these diseases, and contributes to the growing public health issue of antibiotic resistant bacteria. bacteria that cause utis originate from the bowel. in an effort to reduce the number of utis, investigators want to exchange the bacteria living in our bowels for a more harmless variety. hypothesis and specific aims: investigators hypothesize a probiotic comprised of a probiotic bacteria will change the bowel bacteria, thereby reducing the numbers of infection-causing bacteria, thus reducing frequency of utis in healthy patients with recurrent utis and those patients with urinary tract problems that require use of catheters to empty their bladders. aim 1: investigators plan to challenge infection-causing bacteria like pseudomonas species, enterococcus species, and klebsiella species to live in the same environment with the probiotic bacteria to see how the numbers of each bacteria change. aim 2: investigators will culture bacteria that live on urinary catheters and then challenge them to live in the same environment as the probiotic bacteria. potential impact: this novel treatment prevents utis by exchanging a patient's bowel bacteria for a harmless bacteria and reduces the use of antibiotics overall in the community.


Eligibility criteria:
inclusion criteria: * patients with urinary catheters placed that will be getting them removed exclusion criteria: * patient's currently getting treated for uti

Keywords: nissle 1917 probiotic uropathogen
molecular profiling to improve outcome of patients in cancer. a pilot study

Conditions: Colorectal Carcinoma; Soft Tissue Sarcoma

Summary: next generation sequencing in cancer: a feasibility study in france to assess sample circuit and to perform analyzes within a limited time.

the first france disease genomic medicine program in the field of cancer has been retained by the 2025 genomic medicine france plan. this program, called multipli encompasses two innovative personalized medicine clinical trials in soft-tissue sarcoma and colorectal carcinoma involving targeted molecules according to the tumor profile of each patient. this 1st clinical research program aims implementing exome sequencing and rna sequencing to determine the genomic profile and to provide a therapeutic decision for each patient. genomic analyzes will be performed on different technical platforms: samples will be collected in each investigating center, nucleic acids extraction will be performed on two genetic platforms, inca labeled and identified for the purpose of this study: institut bergonié and hôpital européen georges pompidou. cnrgh (centre national de recherche en génomique humaine) was retained for operational platform genomics and institut bergonie for bioinformatics data processing. each genomic profile will be discussed within a multidisciplinary tumor board which aims at providing a therapeutic decision for each patient and to propose a targeted treatment in case of actionable molecular alteration. the purpose of this program is to perform analysis on a set of gene, in order to provide results no more than after 6 weeks after the sample arrival on the biopathological platform. this gene panel analysis is based on the predefined list of genes that are direct targets of the drugs available in the multipli program. before implanting this program in a large-scale launch, it was essential to set up a pilot study in order to evaluate both sample's management between several platforms, and the time to report the results, and to verify that it was in line with the objectives set.

Eligibility criteria:
inclusion criteria: * adult patients * disease: advanced and/or metastatic soft-tissue sarcoma or metastatic carcinoma * patient consenting to tumor sequencing, secondary reuse of their data * patient informed about this study exclusion criteria: * n/a

Keywords: next generation sequencing exome rna sequencing soft-tissue sarcoma colorectal carcinoma
randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with marfan syndrome under treatment with beta-blockers

Conditions: Marfan Syndrome

Summary: to study the effect of losartan (an angiotensin receptor blocker-arb) on aortic root growth in patients with marfan syndrome, already treated with beta-blockers (bb). the effect of losartan will be compared to placebo. losartan or placebo will be added to the treatment regimen in a two-step up-titration scheme over 2 weeks. start doses of losartan will be 25 mg for subjects under 50kg of weight and 50mg if the weight is over 50kg. uptitration will be guided by the tolerance of the drug by the patients. patients will be contacted by phone call for assessment of side-effects before second step of uptitration. daily maximal doses of losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg


Eligibility criteria:
inclusion criteria: * patients \> 10 years * diagnosis of mfs, according to the ghent criteria and/or genetically proven fbn1 mutations or linkage * consent obtained (written) either for the patient and for his/her parents (\<18y * z-score of the aorta at the level of the sinus of valsalva ≥2 (bsa adjusted) * arb naïve patients exclusion criteria: * poor echocardiographic window,limiting the accurate measurement of the aortic root * contra-indication for arb: bilateral renal artery stenosis, renal function abnormalities (creatinine above normal for age), hyperkalemia * intolerance for arb (eg angioedema) * pregnancy or breast feeding women * absence of effective contraception * liver function abnormalities * heart failure * patients included in other clinical trial
clinical study of pet/ct and association with metabolic syndrome/depressive symptoms in psoriasis

Conditions: Psoriasis; Metabolic Syndrome; Depression

Summary: psoriasis is associated with increases in markers of inflammation in the skin and blood and increasingly is thought to be a systemic inflammatory disease and risk factor for incident diabetes mellitus, myocardial infarction, stroke, and premature cardiovascular death. furthermore, it is important for clinicians to be aware that psoriasis can have a substantial emotional impact on an individual, which is not necessarily related to the extent of skin disease. fdg-pet/ct represents an innovative approach to studying systemic inflammation in a manner that is sensitive, quantifiable, and anatomically localizable. also, recent study show that chronic disease such as end stage renal disease with depressive symptoms have decreased cerebral glucose metabolism in several brain areas in f-18-fdg pet/ct. so this protocol was designed to evaluate usefulness of pet/ct to detect systemic inflammation and abnormality of cerebral glucose metabolism and association with metabolic syndrome/major depressive symptoms in patients with psoriasis.

10 patients with psoriasis 1. evaluate pasi score 2. evaluate comorbidity with metabolic syndrome * body mass index(bmi) * checking blood pressure * checking blood sugar * smoking and drinking history * checking blood cholesterol level * risk factors of cardiovascular disease 3. pet/ct for measuring the extent and site of psoriasis with inflammation

Eligibility criteria:
inclusion criteria: * histological diagnosis of plaque type psoriasis * at least 18 years old exclusion criteria: * those who cannot understand questionnaire * those who take antidepressant
a dose escalation study of pf-06939999 in participants with advanced or metastatic solid tumors

Conditions: Advanced Solid Tumors; Metastatic Solid Tumors

Summary: this is a phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, pk, and pharmacodynamics study of pf 06939999 in previously treated patients with advanced or metastatic cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed locally advanced or metastatic nsclc, urothelial carcinoma or hnscc * progressed after at least 1 line of treatment and no more than 3 lines of treatment * at least one measurable lesion as defined by recist version 1.1 * ecog performance status 0 or 1 * adequate bone marrow function * adequate renal function * adequate liver function * resolved acute effects of any prior therapy exclusion criteria: * known active uncontrolled or symptomatic cns metastases. * major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. * active, uncontrolled infection, including covid-19 * known or suspected hypersensitivity to pf-06939999 * inability to consume or absorb study drug
effects of cognitive intervention for older adults with memory decline: a pilot study

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to evaluate the effects of training in memory skills vs. use of external memory aids on everyday memory functioning in older people with mild cognitive impairment.

some older people experience memory loss that is worse than other people of their age, although they are not demented. this condition is known as mild cognitive impairment (mci). healthy older people can learn mnemonic strategies to improve their memory abilities. can cognitive rehabilitation help people with mci do better on mental tasks or maintain better functioning in everyday life? this study will evaluate the effects of two different rehabilitation programmes. patients in the memory training group will learn mental strategies aimed at improving memory. patients in the memory compensation group will learn to use external memory aids.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment exclusion criteria: * unable to speak and understand english * unable to comply with treatment program due to significant comorbid illness; or * anticipated inability to attend all study sessions

Keywords: cognitive training cognitive rehabilitation
phase i/ii azd8931/paclitaxel in treatment of advanced solid tumours (phase i) and advanced breast cancer (phase ii)

Conditions: Neoplasms; Breast Neoplasms; Breast Cancer

Summary: the main purpose of this study is to determine if azd8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer. this study will be conducted in 2 parts: the first part (phase i) will determine a dose of azd8931 that can be safely administered with paclitaxel chemotherapy. the second part (phase ii) will determine the efficacy and safety of azd8931 in combination with paclitaxel chemotherapy in breast cancer.


Eligibility criteria:
inclusion criteria: * male/ female with solid, malignant tumour which is unresponsive to standard therapies (phase i). female patients with advanced breast cancer with low her2 expression (phase ii) * suitable for paclitaxel chemotherapy * life expectancy more than 12 weeks exclusion criteria: * inadequate kidney, liver, heart, gastric, lung or eye function * hypersensitive to paclitaxel * no symptomatic uncontrolled brain metastases * previous taxane chemotherapy within 12 months (phase ii)

Keywords: cancer tumour breast cancer metastatic secondary
hepatocyte growth factor and cardiovascular autonomic function

Conditions: Type-2 Diabetes

Summary: in this study, we tested the hypothesis that elevated hgf is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.


Eligibility criteria:
inclusion criteria: * type-2 diabetes exclusion criteria: * type-1 diabetes
prevalence of long-term dental effects of chemotherapy in childhood cancer survivors diagnosed with cancer before the age of 10

Conditions: Chemotherapy Effect; Dental Caries; Malocclusion; Childhood Cancer; Tooth Defect

Summary: to date, there are no methods for assessing the risk of oral developmental defects that could predict long-term adverse effects in childhood cancer survivors. having such a method at our disposal would enable us to better assess the risk to develop those defects and will help us provide new prevention and treatment strategies to ensure a healthy oral development. the aims of this study are : * assess the caries risk in childhood cancer survivors compared with a control group. * assess the dental development defects risk in childhood cancer survivors compared with a control group.

this will be an international study comparing the childhood cancer survivors (ccs) and a control group. a questionnaire will be provided to the patients to gather information. a standard of care dental examination will then take place in a dental office in the cliniques universitaires saint-luc. we also collect medical data to complete the files.

Eligibility criteria:
inclusion criteria: * age below 10 at cancer diagnosis (for the ccs group). * chemotherapy must have been used to treat the patient (for the ccs group). * the patient is 12 years old or older at the time of the follow-up appointment of the present study exclusion criteria: * a patient who was diagnosed and treated after 10 years old. * patient below 12 years old at time of study recruitment * patients with syndrome or diseases that involve teeth impairment\* * pregnant patient * refusal or inaptitude to undergo dental and radiographic examination

Keywords: childhood cancer survivors dental defect